Pfizer Inc., Amgen Inc., and Boehringer Ingelheim International GmbH enhance their positions by developing novel therapies and collaborating with other companies for strategic market growth
Primary discontinuation was defined as the first date a patient went 60 days or more without any GLP-1based treatment on hand, using fill dates and number of days of medication supplied to account for excess (carryover) medication from previous fills
The Facebook page has also made several other posts about GLP-1 medicines
Despite such benefits, concerns about pancreatitis, pancreatic ductal hyperplasia, pancreatic cancer and thyroid cancer remain in long-term incretin-based treatment due to the effects of GLP-1 on cell growth and proliferation [9,10,11,12,13]
The synergistic enhancement theory proposes that GIP and GLP-1 dont just add to each other but actually amplify each others effects
Covidence systematic review software